Explore 3 Stock Ideas & Industry Insights Download Free Report

mid-cap

Market Update On One HealthCare Stock- CTEC

Aug 13, 2024 | Team Kalkine
Market Update On One HealthCare Stock- CTEC

  • CTEC:LSE
  • Investment Type
    Mid - Cap
  • Risk Level
  • Action
  • Rec. Price (GBX)

ConvaTec Group PLC

ConvaTec Group PLC (LSE: CTEC) is an FTSE 100-listed medical products and technologies company. The company is employed in developing, manufacturing, and selling of medical products. Predominantly, the healthcare entity focuses upon solutions of chronic solutions for the management.

H1 FY24 Interim Results (Released on 30 July 2024)

  • Financial Update: During H1 FY24 the adjusted operating profit reached USD 222.8 mn, marking an 8.2% increase from USD 214.1 mn in H1 FY23 when evaluated on a constant currency basis. The reported operating profit also rose to USD 149.2 mn from USD 123.4 mn in the previous year. The adjusted operating margin was recorded at 20.0%, slightly down from 20.3% in H1 2023, but improved to 20.7% on a constant currency basis.
  • Strategic Progress: The company's innovation pipeline is successfully driving growth in market shares across several product lines. InnovaMatrix® has demonstrated strong growth, bolstered by favorable real-world evidence. ConvaFoamTM has gained traction, securing over half of its product evaluations in the USA. The introduction of Esteem BodyTM is advancing, showing an increase in new patient starts. GentleCathTM Air for Women, launched in France, is expanding its market share in the female compact segment.
  • Outlook: For 2024, the company now expects organic revenue growth to be in the upper half of the 5-7% range, with an adjusted operating profit margin of at least 21.0% on a constant currency basis. It also anticipates double-digit growth in both adjusted earnings per share (EPS) and free cash flow to equity. Over the medium term, the company projects continued organic revenue growth of 5-7% annually, aims for a margin expansion to the mid-20s by 2026 or 2027 and seeks to achieve double-digit compound annual growth in adjusted.

Share Price Chart

Markets are trading in a highly volatile zone currently due to certain macroeconomic issues and geopolitical tensions prevailing. Therefore, it is prudent to follow a cautious approach while investing.

ConvaTec Group PLC (LSE: CTEC) was trading at the current market price of GBX 231.20  (as of 13 August 2024, 08:30 AM GMT+1) 

Note 1: Past performance is not a reliable indicator of future performance.

Note 2: The reference date for all price data, currency, technical indicators, support, and resistance level is 13 August 2024. The reference data in this report has been partly sourced from REFINITIV.

Note 3: ‘Kalkine reports are prepared based on the stock prices captured either from the London Stock Exchange (LSE) and or REFINITIV. Typically, both sources (LSE and or REFINITIV) may reflect stock prices with a delay which could be a lag of 15-20 minutes. There can be no assurance that future results or events will be consistent with the information provided in the report. The information is subject to change without any prior notice.

Note 4: Dividend Yield may vary as per the stock price movement.


Disclaimer-

This report has been issued by Kalkine Limited (Company number 07903332), a private limited company, incorporated in England and Wales ("Kalkine”). Kalkine.co.uk and associated pages are published by Kalkine. Kalkine is authorised and regulated by the Financial Conduct Authority under reference number 579414.

The information in this report and on the Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of information contained in its reports, newsletters and websites.  All information represents our views at the date of publication and may change without notice. The information in this report does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products. Our reports contain non personalized recommendations to invest in securities and other financial products.

Kalkine does not offer financial advice based upon your personal financial situation or goals, and we shall not be held liable for any investment or trading losses you may incur by using the opinions expressed in our reports, publications, market updates, news alerts and corporate profiles. Kalkine does not intend to exclude any liability which it is not permitted to exclude under applicable law or regulation. Kalkine’s non-personalised advice does not in any way endorse or recommend individuals, investment products or services for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a professional authorised financial planner and adviser. You should be aware that the value of any investment and the income from it can go down as well as up and you may not get back the amount invested.

Please also read our Terms & Conditions for further information. Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this report or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Kalkine Media Limited, an affiliate of Kalkine, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website including entities covered in this report.

Past performance is not a reliable indicator of future performance.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions